S2 Genomics, a Livermore, CA-based manufacturer of tissue sample preparation systems for single cell genomics assays, raised $16M in Series A funding.
Backers included BroadOak Capital Partners and Research Corporation Technologies (RCT).
Led by Jonathan Schimmel, President and CEO, S2 Genomics is a global life science tools company which provides proprietary Singulator platform that automates the preparation of single cell and single nuclei suspensions from solid tissues for single cell genomics applications, enabling single cell biology for every scientist. Since its first commercial launch in 2020, Singulator has been adopted globally by leading academic research organizations, pharmaceutical companies, biotech companies and service providers. The platform is comprised of three components: a benchtop instrument, single-use consumables, and more than 80 validated protocols for single cell or single nuclei sample preparation from different tissue types.
The company intends to use the funds to accelerate the commercial adoption of its benchtop Singulator platform, which utilizes single-use cartridges to enable reproducible, rapid, and automated tissue dissociations into single cell or nuclei suspensions. Customers use suspensions of nuclei and high-viability cells produced by the Singulator to advance neuroscience and oncology research.
Commenting on the news, Jonathan Schimmel said: “In addition to their investment, BroadOak and RCT bring a wealth of knowledge and experience in our field, and we look forward to their support to drive our next stage of growth.”
